Scilex Holding (SCLXW) Shares Outstanding (Diluted Average) (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Shares Outstanding (Diluted Average) of $6.9 million in Q1 2026, up 62352.42% quarter-over-quarter from $11034.0 in Q4 2025, and down 40.42% on a YoY basis from $11.6 million in Q1 2025.
Scilex Holding (SCLXW) Shares Outstanding (Diluted Average) (2020 - 2026) Analysis & Trends
Scilex Holding's Shares Outstanding (Diluted Average) history runs 7 years deep, the most recent figure standing at $6.9 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) fell 40.42% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (down 40.42% YoY), while the FY2025 annual figure was $11034.0, up 8.76% from the prior year.
- Shares Outstanding (Diluted Average) was $6.9 million for Q1 2026 at Scilex Holding, up from $11034.0 in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $134.2 million in Q4 2022 to a low of $2926.0 in Q1 2024.
- Historically, Shares Outstanding (Diluted Average) has averaged $40.2 million across 5 years, with a median of $141660.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Diluted Average) tumbled 99.99% in 2024, then jumped 395149.49% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $134.2 million in 2022, then decreased by 2.93% to $130.3 million in 2023, then sank by 99.99% to $10145.0 in 2024, then grew by 8.76% to $11034.0 in 2025, then soared by 62352.42% to $6.9 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $6.9 million (Q1 2026), $11034.0 (Q4 2025), and $11604.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 895.90 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.45 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 1.77 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 544.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.25 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 5.73 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Scilex Holding | - | - | 4.15 Mn | 6.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.89 Mn |
| Dec 31, 2025 | 11,034.00 |
| Sep 30, 2025 | 11,604.00 |
| Jun 30, 2025 | 11,595.00 |
| Mar 31, 2025 | 11.57 Mn |
| Dec 31, 2024 | 10,145.00 |
| Sep 30, 2024 | 5,194.00 |
| Jun 30, 2024 | 3,999.00 |
| Mar 31, 2024 | 2,926.00 |
| Dec 31, 2023 | 130.30 Mn |
| Sep 30, 2023 | 141,358.00 |
| Jun 30, 2023 | 142,146.00 |
| Mar 31, 2023 | 141,660.00 |
| Dec 31, 2022 | 134.23 Mn |
| Sep 30, 2022 | 133.28 Mn |
| Jun 30, 2022 | 133.04 Mn |
| Mar 31, 2022 | 133.03 Mn |
| Dec 31, 2021 | 132.86 Mn |
| Sep 30, 2021 | 16.68 Mn |
| Jun 30, 2021 | 17.25 Mn |